Skip to Content
Merck

Key Documents

View All Documentation

EHU156391

MISSION® esiRNA

targeting human MIIP

Sign In to View Organizational & Contract Pricing.

Select a Size

Change View

About This Item

NACRES:
NA.51
UNSPSC Code:
41105324
Technical Service
Need help? Our team of experienced scientists is here for you.
Let Us Assist

description

Powered by Eupheria Biotech

Quality Level

100

product line

MISSION®

form

lyophilized powder

esiRNA cDNA target sequence

CGTCCTCAACTTCCTTGAGCACCTCCTGCCCACGGGGCCGGTCCTCCGTGTGGGGCCCACCAGATGCCTGTCGAGGGGACCTCCGTGATGTGGCCAGATCGGGGGTGGCCTCTCTCCCACCTGCCAAATGCCAGCACCAGGAGTCCCTGGGCCGACCGAGACCCCACTCAGCACCCTCGCTGGGCACCTCAAGCCTGAGGGACCCAGAGCCCTCAGGGAGGCTGGGTGATCCAGGACCCCAGGAGGCACAGACCCCGAGGTCCATCCTGGCTCAACAGAGCAAGCTGTCCAAGCCCAGGGTGACCTTCTCTGAGGAGTCTGCAGTTCCTAAGAGGAGCTGGCGCCTCAGGCCATACCTGGGCTATGACTGGATTGCAGGGTCTCTGGACACCAGCTCTTCC

Ensembl | human accession no.

ENSG00000116691

NCBI accession no.

NM_021933

shipped in

ambient

storage temp.

−20°C

Gene Information

human ... MIIP(60672)

General description

MISSION esiRNA are endoribonuclease prepared siRNA. They are a heterogeneous mixture of siRNA that all target the same mRNA sequence. These multiple silencing triggers lead to highly-specific and effective gene silencing.

For additional details as well as to view all available esiRNA options, please visit SigmaAldrich.com/esiRNA.

Legal Information

MISSION is a registered trademark of Merck KGaA, Darmstadt, Germany

Choose from one of the most recent versions:

Certificates of Analysis (COA)

Lot/Batch Number
FXS
XHS
RWR

Don't see the Right Version?

If you require a particular version, you can look up a specific certificate by the Lot or Batch number.

Search for a COA

Already Own This Product?

Find documentation for the products that you have recently purchased in the Document Library.

Visit the Document Library

Wei Hu et al.
American journal of cancer research, 10(2), 630-647 (2020-03-21)
Growing evidence have shown that the migration and invasion inhibitory protein (MIIP, also known as IIp45) functions as a tumor suppressor and its expression is downregulated in several types of cancer, yet the function of MIIP in prostate cancer (PCa)